Cargando…
Corrigendum: First‐in‐human study of milvexian, an oral, direct, small molecule factor XIa inhibitor
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9010251/ https://www.ncbi.nlm.nih.gov/pubmed/35239991 http://dx.doi.org/10.1111/cts.13258 |
Ejemplares similares
-
First‐in‐human study of milvexian, an oral, direct, small molecule factor XIa inhibitor
por: Perera, Vidya, et al.
Publicado: (2021) -
Effects of rifampin on the pharmacokinetics and pharmacodynamics of milvexian, a potent, selective, oral small molecule factor XIa inhibitor
por: Perera, Vidya, et al.
Publicado: (2022) -
Milvexian, an orally bioavailable, small‐molecule, reversible, direct inhibitor of factor XIa: In vitro studies and in vivo evaluation in experimental thrombosis in rabbits
por: Wong, Pancras C., et al.
Publicado: (2021) -
Effects of Itraconazole and Diltiazem on the Pharmacokinetics and Pharmacodynamics of Milvexian, A Factor XIa Inhibitor
por: Perera, Vidya, et al.
Publicado: (2022) -
Antithrombotic Effects of the Novel Small-Molecule Factor XIa Inhibitor Milvexian in a Rabbit Arteriovenous Shunt Model of Venous Thrombosis
por: Wang, Xinkang, et al.
Publicado: (2023)